[go: up one dir, main page]

MX2023011166A - Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. - Google Patents

Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.

Info

Publication number
MX2023011166A
MX2023011166A MX2023011166A MX2023011166A MX2023011166A MX 2023011166 A MX2023011166 A MX 2023011166A MX 2023011166 A MX2023011166 A MX 2023011166A MX 2023011166 A MX2023011166 A MX 2023011166A MX 2023011166 A MX2023011166 A MX 2023011166A
Authority
MX
Mexico
Prior art keywords
preparation
medicine
compound
method therefor
tetrahydronaphthalene compound
Prior art date
Application number
MX2023011166A
Other languages
English (en)
Inventor
Nan Yu
Feng He
Weikang Tao
Fanglong Yang
Zhiwei Liu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023011166A publication Critical patent/MX2023011166A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a un compuesto de tetrahidronaftaleno y a un método de preparación del mismo, y a su uso en medicina. Específicamente, la presente divulgación se refiere a un compuesto de tetrahidronaftaleno representado por la fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el compuesto y el uso del mismo como agente terapéutico, en particular su uso como degradador del receptor de estrógeno., el uso en la preparación de un fármaco para tratar y/o prevenir enfermedades o afecciones dependientes o mediadas por receptores de estrógeno y el uso en la preparación de un fármaco para tratar y/o prevenir enfermedades o afecciones utilizando la degradación de una proteína diana. (ver Fórmula).
MX2023011166A 2021-03-29 2022-03-29 Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. MX2023011166A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110332995 2021-03-29
CN202110666964 2021-06-16
CN202110870938 2021-07-30
CN202111097026 2021-09-18
PCT/CN2022/083597 WO2022206737A1 (zh) 2021-03-29 2022-03-29 四氢萘类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023011166A true MX2023011166A (es) 2023-09-29

Family

ID=83457960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011166A MX2023011166A (es) 2021-03-29 2022-03-29 Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.

Country Status (11)

Country Link
US (1) US20250099596A1 (es)
EP (1) EP4317146A4 (es)
JP (1) JP2024512544A (es)
KR (1) KR20230164093A (es)
CN (1) CN116917280A (es)
AU (1) AU2022250316A1 (es)
BR (1) BR112023019967A2 (es)
CA (1) CA3211378A1 (es)
MX (1) MX2023011166A (es)
TW (1) TW202302567A (es)
WO (1) WO2022206737A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
EP4596538A4 (en) * 2022-09-29 2025-12-31 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF TETRAHYDRONAPHTALENE DERIVATIVE, AND PROCESS OF PREPARATION
CN118271284A (zh) * 2022-12-30 2024-07-02 江苏威凯尔医药科技有限公司 雌激素受体调节剂及其用途
WO2025119380A1 (zh) * 2023-12-08 2025-06-12 江苏威凯尔医药科技股份有限公司 雌激素受体调节剂及其用途
WO2025240252A1 (en) * 2024-05-13 2025-11-20 Beta Pharma, Inc. Estrogen receptor degraders as treatments for breast cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160845A2 (en) * 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP6873433B2 (ja) 2015-06-04 2021-05-19 アルヴィナス・オペレーションズ・インコーポレイテッド タンパク質分解のイミド系修飾因子および関連の使用方法
US10399939B2 (en) * 2015-11-09 2019-09-03 Genentech, Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
JP6957620B2 (ja) * 2016-12-01 2021-11-02 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR20210003804A (ko) * 2018-04-13 2021-01-12 아비나스 오퍼레이션스, 인코포레이티드 세레브론 리간드 및 이를 포함하는 2작용성 화합물
MX2022002415A (es) * 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
CN115003295B (zh) 2019-12-12 2025-05-06 冰洲石生物科技公司 具有雌激素受体降解活性的新型色满衍生物及其用途

Also Published As

Publication number Publication date
TW202302567A (zh) 2023-01-16
KR20230164093A (ko) 2023-12-01
US20250099596A1 (en) 2025-03-27
AU2022250316A1 (en) 2023-10-12
EP4317146A1 (en) 2024-02-07
CA3211378A1 (en) 2022-10-06
BR112023019967A2 (pt) 2023-11-14
CN116917280A (zh) 2023-10-20
JP2024512544A (ja) 2024-03-19
WO2022206737A1 (zh) 2022-10-06
EP4317146A4 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
BR112022014398A2 (pt) Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
BR112022013322A2 (pt) Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina
MX2024007938A (es) Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead.
UY33470A (es) Derivados de 6,7-dihidro-5h-benzo[7]anulenos, métodos para su preparación, preparaciones farmacéuticas que los contienen y su uso para la preparación de medicamentos
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
BR112014031649A2 (pt) composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
BR112023001924A2 (pt) Derivados de benzimidazol, método de preparo para os mesmos e uso médico dos mesmos
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
CO2025006863A2 (es) Métodos para el tratamiento de la obesidad
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso